FDA Determines Regulatory Review Period for MENHIBRIX Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of human biological product MENHIBRIX, as required by law, following submissions to the Director of Patents and Trademarks at the US Department of Commerce.